http://www.twitter.comTwitter is a service for friends, family, and co-workers to communicate and stay connected through the exchange of quick, frequent answers to one simple question: What are you doing?
View Older Stories View More Recent Stories
-
Transgene, NEC and BostonGene Announce Strategic Collaboration for Two Ongoing Clinical Trials for Patients with Ovarian and Head & Neck Cancers
-
Transgene: Positive Clinical Results for TG4001 and TG6002 and Financial Visibility Secured Until 2022
-
Transgene Announces Upcoming Investor Meetings
-
Positive Initial Data From a Phase 1 Trial With Transgene’s Oncolytic Virus TG6002
-
Transgene Receives $22.2 Million from the Sale of Part of its Minority Stake in Tasly BioPharmaceuticals
-
Transgene Reports Results From Clinical Study of TG4001 in Combination With Avelumab in Advanced HPV-Positive Cancers
-
Transgene and Hypertrust Patient Data Care Announce Successful Go-Live of the World’s First Blockchain Solution for Clinical Trials of Personalized Healthcare
-
BioInvent and Transgene's BT-001 Achieves Outstanding Tumor Cure Rates in Preclinical Models
-
Transgene Presents Promising New Data from its Next-Generation Immunotherapy Platforms at AACR 2020
-
Transgene’s and BioInvent’s BT-001 Achieves Outstanding Tumor Cure Rates in Preclinical Models
-
BioInvent and Transgene Present Preclinical Data Demonstrating BT-001's Powerful Activity Against Solid Tumors
-
Transgene and BioInvent Present Preclinical Data Demonstrating BT-001’s Powerful Activity Against Solid Tumors
-
Transgene and NEC Demonstrate High Accuracy of AI-Based Neoantigen Prediction for the Design of Individualized Cancer Vaccine TG4050
-
Transgene Reports Q1 2020 Financial Position and Business Update
-
Vaxxel Acquires Transgene's DuckCelt®-T17 Cell Line to Develop Industrial-scale Vaccines Against Respiratory Viruses
-
Transgene: Availability of Preparatory Documents for the Combined General Meeting of May 27, 2020
-
Transgene: Major R&D Milestones Achieved in 2019 and Strong Clinical Activity In 2020
-
BioInvent and Transgene to Present Data on BT-001, an Oncolytic Virus Encoding for an Anti-CTLA4 Antibody, at Upcoming Congresses
-
Transgene and BioInvent to Present Data on BT-001, an Oncolytic Virus Encoding for an Anti-CTLA4 Antibody, at Upcoming Congresses
-
First Patient Dosed With Transgene’s Oncolytic Virus TG6002, Administered by Intrahepatic Artery Infusion in Colorectal Cancer With Liver Metastases
-
Transgene and NEC Start Two Clinical Trials with TG4050, an Individualized AI-Powered Cancer Vaccine for Ovarian and Head & Neck Cancers
-
Transgene Announces Financial Calendar for 2020
-
Transgene Reports on the Combination Trial of TG4010, Chemotherapy and Nivolumab in Non-Small Cell Lung Cancer
-
BioInvent and Transgene Announce Compelling Preclinical Data for BT-001 in Solid Tumors
-
Transgene and BioInvent Announce Compelling Preclinical Data For BT-001 in Solid Tumors
-
Transgene Announces Investor Meetings for January 2020
-
Transgene Provides Q3 2019 Business Update, with Focus on Recently Announced Efficacy Results of TG4001
-
Transgene Will Participate in the Jefferies 2019 London Healthcare Conference
-
Transgene Reports First Promising Efficacy Results with TG4001 in Combination with Avelumab in HPV-Positive Cancer at ESMO 2019
-
Transgene Confirms the Timeline of its Clinical News Flow and Presents 2019 Half-Year Results
-
Transgene Confirms the Timeline of its Clinical News Flow and Presents 2019 Half-Year Results
-
Transgene Receives Approval from the French Health Authority (ANSM) to Initiate Two Clinical Trials of its Lead myvac™ Individualized Immunotherapy TG4050
-
Transgene Announces Upcoming Investor Meetings
-
Transgene Provides an Update after the Interim Futility Analysis of the PHOCUS Study of Pexa-Vec in Liver Cancer
-
Transgene Provides Update on PHOCUS Study of Pexa-Vec in Liver Cancer Following Planned Interim Futility Analysis
-
Transgene Receives MHRA Approval for a Clinical Trial of TG6002, a Next-generation Oncolytic Virus, Administered by Intrahepatic Artery Infusion in Patients with Colorectal Cancer with Liver Metastase
-
Transgene Receives MHRA Approval for Lead myvac™ Individualized Immunotherapy, TG4050, to Commence Clinical Development in HPV Negative Head and Neck Cancers in the UK
-
Transgene: Peer-Reviewed Publications Confirm the Potential of Transgene’s TG4001 and TG6002
-
Last Patient Enrolled in the Phase 2 Trial with Transgene’s TG4010 + Nivolumab + Chemotherapy for the First-Line Treatment of Advanced Lung Cancer (NSCLC)
-
Transgene: Financial Visibility Extended to Q4 2020, Including $10 Million Revenue from Collaboration with AstraZeneca to Be Received in Q2 2019
-
Transgene receives FDA IND Clearance for Lead myvac™ Individualized Immunotherapy, TG4050, to Commence Clinical Development in Ovarian Cancer
-
Transgene Announces Upcoming Investor Meetings
-
Transgene: Availability of Preparatory Documents for the Combined General Meeting of May 22, 2019
-
Transgene and AstraZeneca enter into a collaboration and exclusive license option agreement for innovative Invir.IOTM based armed oncolytic immunotherapies
-
BioInvent and Transgene Extend Their Collaboration to Develop Multifunctional Oncolytic Viruses for the Treatment of Solid Tumors
-
Transgene and BioInvent Extend their Collaboration to Develop Multifunctional Oncolytic Viruses for the Treatment of Solid Tumors
-
Transgene: A Positive 2018, Moving Ahead with a Strong Portfolio
-
Transgene Secures a €20 Million Revolving Credit Facility with Natixis
-
Transgene - NEOVIVA Project Supporting the Development of myvac™ Awarded a €5.2 Million Grant from Bpifrance’s “Investments for the Future” Programme
-
Transgene to start clinical development of lead myvacTM individualized immunotherapy, TG4050, in 2019, under its partnership with NEC
